Figure 4 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers

Figure 4 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers

<p>Single-gene expression changes of genes in common between baseline and surgery in the different cohorts. <b>A,</b> Scatterplot of differentially expressed genes between baseline and surgery measured by log<sub>2</sub> FC among the entire short-term and long-term AI c...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile nagusia: Milana A. Bergamino (15038015) (author)
Beste egile batzuk: Gabriele Morani (15038018) (author), Joel Parker (15038021) (author), Eugene F. Schuster (9726535) (author), Mariana F. Leal (15038024) (author), Elena López-Knowles (15038027) (author), Holly Tovey (9360536) (author), Judith M. Bliss (8827107) (author), John F.R. Robertson (15025368) (author), Ian E. Smith (1545553) (author), Mitch Dowsett (645) (author), Maggie C.U. Cheang (14946768) (author)
Argitaratua: 2025
Gaiak:
Cancer
Tumor Biology
Cancer Detection and Diagnosis
Therapeutic Research and Development
Biomarkers
Genetic biomarkers
Breast Cancer
Drug Resistance
Novel mechanisms
Endocrinology
Translational Research
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
Deskribapena
Gaia:<p>Single-gene expression changes of genes in common between baseline and surgery in the different cohorts. <b>A,</b> Scatterplot of differentially expressed genes between baseline and surgery measured by log<sub>2</sub> FC among the entire short-term and long-term AI cohorts. <b>B,</b> Scatterplot of differentially expressed genes between baseline and surgery measured by log<sub>2</sub> FC among Luminal B–treated tumors only in the short-term and long-term AI cohorts <b>C,</b> Boxplot showing the intersections of common genes differentially expressed between baseline and surgery among different combinations of subgroups of sample patients within the POETIC and NeoAI cohorts: all treated patients in POETIC, only treated with Luminal A in POETIC, only treated with Luminal B in POETIC, all patients in NeoAI, only Luminal A in NeoAI, only Luminal B patients in NeoAI, only controls in POETIC. FDR, false discovery rate; log<sub>2</sub> FC, log<sub>2</sub> fold change.</p>

Antzeko izenburuak